<DOC>
	<DOCNO>NCT00004132</DOCNO>
	<brief_summary>RATIONALE : Keratinocyte growth factor may prevent symptom mucositis patient receive radiation therapy chemotherapy . PURPOSE : Randomized phase II trial study effectiveness keratinocyte growth factor prevent oral mucositis patient hematologic cancer undergo radiation therapy chemotherapy autologous peripheral stem cell transplantation .</brief_summary>
	<brief_title>Growth Factor Prevent Oral Mucositis Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy recombinant keratinocyte growth factor reduce duration severe oral mucositis induce total body irradiation high dose chemotherapy patient hematologic malignancy . II . Determine incidence duration severe oral mucositis , grade 2-4 diarrhea , febrile neutropenia patient . III . Determine necessity use transdermal parenteral opioid analgesic IV antifungal antibiotic febrile neutropenia infection patient . IV . Determine quality life patient . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify center . Patients randomize one three treatment arm . Arm I : Patients receive 7 dos recombinant human keratinocyte growth factor ( rHuKGF ) . Arm II : Patients receive 4 dos rHuKGF follow 3 dos placebo . Arm III : Patients receive 7 dos placebo . Patients receive one two conditioning regimen . Primary condition regimen : Patients receive rHuKGF placebo daily day -11 , -10 , -9 , -5 , 0 , 1 , 2 . Total body irradiation ( TBI ) administer twice day day -8 -5 . Patients receive etoposide day -4 , cyclophosphamide IV 1 hour day -2 , peripheral blood stem cell transplantation ( PBSCT ) day 0 . Filgrastim ( G-CSF ) IV SC administer begin day 0 continue 21 day blood count recover . Secondary condition regimen : Patients receive rHuKGF placebo daily day -13 , -12 , -11 , -7 , 0 , 1 , 2 . TBI administer twice day day -10 -7 . Patients receive ifosfamide IV 1 hour follow etoposide 23 hour day -6 -2 , PBSCT day 0 . G-CSF IV SC administer begin day 0 21 day blood count recover . Quality life assess daily begin day -11 continue day 28 . Patients follow day 28 day 60-100 . PROJECTED ACCRUAL : A minimum 111 patient ( 37 per arm ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis NonHodgkin 's lymphoma , Hodgkin 's disease , acute myelogenous leukemia , acute lymphoblastic leukemia , chronic myelogenous leukemia , chronic lymphocytic leukemia , multiple myeloma Eligible total body irradiation plus high dose chemotherapy follow autologous peripheral blood stem cell transplantation At least 1,500,000 CD34+ cells/kg cryopreserved No prior treatment study PATIENT CHARACTERISTICS : Age : 12 65 Performance status : Karnofsky 70100 % SWOG 0 1 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1000/mm3 Platelet count great 100,000/mm3 If condition regimen schedule soon apheresis , platelet count great 50,000/mm3 less 100,000/mm3 allow Hepatic : Bilirubin great 2 mg/dL Renal : Creatinine great 2 mg/dL Cardiovascular : No congestive heart failure No New York Heart Association class III IV heart disease Pulmonary : DLCO least 50 % predict Other : No prior concurrent second malignancy No active infection oral mucositis No insulin dependent diabetes mellitus HIV negative No sensitivity E. coli derive product Not pregnant nursing Fertile patient must use effective contraception one month , , one month study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow peripheral blood stem cell transplantation , unless undergo second transplant tandem transplant regimen , complication first transplant No concurrent interleukin11 Chemotherapy : No concurrent cytotoxic chemotherapy , except intrathecal methotrexate CNS involvement Endocrine therapy : Not specify Radiotherapy : No prior extensive radiotherapy would preclude total body irradiation Surgery : Not specify Other : At least 30 day since prior investigational device drug , except Baxter Isolex column No concurrent investigational agent No concurrent prophylactic oral cryotherapy chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>oral complication</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>